I really tried my best. I've tried running, swimming, fitness, vegetarianism and so on, but I just can't eat this damn meat. Not that I can't, I can only blame myself for my strong digestion and absorption ability. After high-intensity exercise, others rewarded themselves with beautiful steaks with broccoli, a weight-loss vegetable. I only dared to add an extra spoonful of rice and became hungry in the middle of the night. Say with satisfaction ......
Because of the need of work, I have to control my weight at all times, but if I can't lose weight successfully, I can only choose drugs to lose weight. Dare not drink slimming tea, for fear of diarrhea; I don't want to eat L-carnitine, because I know I have enough exercise. The only choice before me is the only OTC diet pill approved by the state-
Orlister is missing. But this thing is a lipase inhibitor. In short, it can only reduce my heat absorption. Does it really work?
I looked up a lot of literature, and finally compiled a manual, suggesting that I use orlistat and share it with you for your reference!
First, the overall efficacy of orlistat
(1) Weight loss effect
Orlistat official website of GlaxoSmithKline pointed out that adding Orlistat 60 mg tid to diet control and moderate exercise can reduce body weight by half compared with simple diet control and moderate exercise. A review published in The Lancet magazine, Volume 87,No. 1003 1 20 16, rated orlistat's weight loss effect as "moderate". Specifically, according to the FDA, the weight loss rate of subjects in orlistat 120 mg tid group and placebo group was -6.6543.
Meta-analysis of 33 randomized controlled clinical trials published in Pharmacol Res.20 122 and Volume 17 showed that compared with placebo, orlistat could significantly reduce the weight of overweight/obese people, and the weighted average difference (hereinafter referred to as WMD) was -2. 12 kg, P.
(2) improve the level of blood lipid metabolism
Many clinical trials have confirmed that orlistat can significantly improve the level of blood lipid metabolism in overweight/obese people. In general, Sa was published in Pharmacol Res 20 122, Volume 17, and was included in the meta-analysis of 33 randomized controlled clinical trials. The results showed that the effect parameters WMD of orlistat and placebo were -0.30mmol/L (total cholesterol, P
It is worth noting that many experiments (such as Erdmann et al. Alien pharmacol ther). ? June 20041; 19 (11):1173-9.) confirmed that the lipid-lowering effect of orlistat was independent of its weight-reducing effect.
(3) Improve blood biochemical indexes related to obesity.
Many clinical trials have confirmed that orlistat can significantly improve adiponectin and other obesity-related blood biochemical indicators. A meta-analysis of 12 randomized controlled clinical trials published by Br J Clin Pharmacol. Journal 20 16, Vol.81,No.5 showed that compared with placebo, orlistat could significantly improve the adiponectin level of subjects (WMD = 19. 18%, 95. 32.57, p = 0.005), and significantly reduced leptin levels (WMD =- 13.24%, 95% CI:-20.69, -5.78, p = 0.00 1) and C-terminal reactive protein (WMD:-). 0.00 1)。
Second, the overall safety characteristics of orlistat
Although orlistat has been criticized for causing "embarrassing" gastrointestinal adverse reactions such as oil spots and defecation, the above-mentioned adverse reactions are all caused by the mechanism that orlistat inhibits lipase activity and fat absorption, and most of them are mild to moderate, which can disappear or relieve themselves. Because the absorption of orlistat after oral administration is extremely low (≤2%), it has no obvious adverse effects on the circulatory system and nervous system, so Bray and others described it as one of the "safest" slimming drugs in their review.
One of the safety defects criticized by orlistat is the risk of liver injury. In May 20 10 and February 20 12, respectively, FDA of the United States and EMA of the European Union reported and evaluated the cases of liver injury during the use of orlistat (including 120mg and 60mg), and the reported incidence rates of liver injury were ≤13/40 million and ≤ 30/respectively. Both FDA and EMA pointed out that in view of the extremely low incidence of liver injury during orlistat administration and considering the following factors, the causal relationship between liver injury and orlistat could not be confirmed. ?
Really don't say anything, Mr. Orlister, I need your help!